{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:42:40Z","timestamp":1787794960306,"version":"build-2784847793"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.01.016","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T06:26:37Z","timestamp":1769927197000},"page":"e619-e630.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Insights Into Acute promyelocytic leukemia (APL) in Egypt in the Absence of Arsenic Trioxide (ATO): Clinical Characteristics, Outcomes and Risk Factors for Early Mortality: A Single Center Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-7651","authenticated-orcid":false,"given":"Yasmine","family":"Shaaban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina N.","family":"Laimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-8988","authenticated-orcid":false,"given":"Esraa","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2026.01.016_bib0001","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41375-018-0139-4","article-title":"Management of patients with acute promyelocytic leukemia","volume":"32","author":"Kayser","year":"2018","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.clml.2026.01.016_bib0002","first-page":"1854","article-title":"Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia","volume":"128","author":"Libourel","year":"2016","journal-title":"Blood, J Am Soc Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.01.016_bib0003","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12185-023-03696-7","article-title":"Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia","volume":"120","author":"Yokoyama","year":"2024","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2026.01.016_bib0004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/a-2238-4782","article-title":"Thrombosis in acute promyelocytic leukemia: the current understanding","volume":"45","author":"Sabljic","year":"2025","journal-title":"Hamostaseologie"},{"issue":"5","key":"10.1016\/j.clml.2026.01.016_bib0005","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s12185-024-03708-0","article-title":"Dysregulated hemostasis in acute promyelocytic leukemia","volume":"119","author":"Hisada","year":"2024","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjmed.2009.09.011","article-title":"Appropriate use of D-dimer in hospital patients","volume":"123","author":"Thachil","year":"2010","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.01.016_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70058","article-title":"Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy","volume":"6","author":"Gong","year":"2025","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Nat Compreh Cancer Netw"},{"issue":"11","key":"10.1016\/j.clml.2026.01.016_bib0009","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s00277-023-05422-z","article-title":"Predictors of very early death in acute promyelocytic leukemia: a retrospective real-world cohort study","volume":"102","author":"Infante","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.01.016_bib0010","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0049-3848(14)50019-9","article-title":"Thrombo-hemorrhagic deaths in acute promyelocytic leukemia","volume":"133","author":"Breccia","year":"2014","journal-title":"Thrombosis Res"},{"issue":"2","key":"10.1016\/j.clml.2026.01.016_bib0011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.clml.2026.01.016_bib0012","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.3390\/cancers15194767","article-title":"Differentiation syndrome in acute leukemia: APL and beyond","volume":"15","author":"Woods","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.clml.2026.01.016_bib0013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.01.016_bib0014","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00432-019-03076-x","article-title":"Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide","volume":"146","author":"Jin","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2026.01.016_bib0015","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.htct.2024.02.020","article-title":"Causes and risk factors for early death in adult patients with acute promyelocytic leukemia: a real-life experience","volume":"46","author":"Fontes","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2026.01.016_bib0016","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/10428194.2021.1894651","article-title":"Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?","volume":"62","author":"Dhakal","year":"2021","journal-title":"Leuk Lymp"},{"issue":"7","key":"10.1016\/j.clml.2026.01.016_bib0017","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3324\/haematol.2021.280093","article-title":"A risk score based on real-world data to predict early death in acute promyelocytic leukemia","volume":"107","author":"\u00d6sterroos","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0018","first-page":"183","article-title":"Study on clinical features of early death in older patients with acute promyelocytic leukemia","volume":"104","author":"Zhao","year":"2025","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1016\/j.clml.2026.01.016_bib0019","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/bloodadvances.2021004789","article-title":"Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study","volume":"5","author":"Gill","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0020","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.clml.2018.08.001","article-title":"Factors affecting early death and survival of patients with acute promyelocytic leukemia treated with ATRA-based therapy regimens","volume":"19","author":"Sun","year":"2019","journal-title":"Clin Lymph Myelom Leuk"},{"issue":"2","key":"10.1016\/j.clml.2026.01.016_bib0021","first-page":"169","article-title":"Improving outcomes of acute promyelocytic leukemia in the current era: analysis of the SEER database","volume":"18","author":"Murthy","year":"2020","journal-title":"J Nat Comprehens Cancer Netw"},{"key":"10.1016\/j.clml.2026.01.016_bib0022","article-title":"Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone","volume":"79","author":"Hou","year":"2019","journal-title":"Blood Cells, Molecul Di"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0023","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12885-023-10612-z","article-title":"Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021","volume":"23","author":"Gill","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clml.2026.01.016_bib0024","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.clml.2022.11.005","article-title":"Improvement of early death in acute promyelocytic leukemia: a population-based analysis","volume":"23","author":"Li","year":"2023","journal-title":"Clin Lymph Myelom Leuk."},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/bjh.19843","article-title":"Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland","volume":"206","author":"Vedi","year":"2025","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2026.01.016_bib0026","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.3390\/cancers16234092","article-title":"Acute promyelocytic leukemia in the real world: understanding outcome differences and how we can improve them","volume":"16","author":"Bidikian","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.clml.2026.01.016_bib0027","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/bloodadvances.2021005642","article-title":"Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States","volume":"6","author":"Bewersdorf","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-022-00619-3","article-title":"Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia","volume":"12","author":"Kulkarni","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2026.01.016_bib0029","first-page":"684","article-title":"Prognostic impact of pretreatment serum lactate dehydrogenase levels in adult patients with acute myeloid leukemia: single center experience","volume":"40","author":"Taalab","year":"2023","journal-title":"Benha Med J"},{"issue":"5","key":"10.1016\/j.clml.2026.01.016_bib0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/hon.2925","article-title":"Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia","volume":"39","author":"Doucette","year":"2021","journal-title":"Hematolog Oncol"},{"issue":"13","key":"10.1016\/j.clml.2026.01.016_bib0031","first-page":"1763","article-title":"Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era","volume":"129","author":"Mantha","year":"2017","journal-title":"Blood J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.01.016_bib0032","series-title":"Acute Myeloid Leukemia in Children: Standard of Care and Future Perspectives","first-page":"133","article-title":"Acute promyelocytic leukemia","author":"Abla","year":"2024"},{"issue":"10","key":"10.1016\/j.clml.2026.01.016_bib0033","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00277-024-05904-8","article-title":"Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients-real world experience","volume":"103","author":"El-Ashwah","year":"2024","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.01.016_bib0034","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.21037\/tcr-20-2179","article-title":"Neutrophil-to-lymphocyte ratio correlates with prognosis and response to chemotherapy in patients with non-M3 de novo acute myeloid leukemia","volume":"10","author":"Zhang","year":"2021","journal-title":"Translation Cancer Res"},{"key":"10.1016\/j.clml.2026.01.016_bib0035","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2018-99-112204","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in relapsed\/refractory acute myeloid leukemia","volume":"132","author":"Mushtaq","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.01.016_bib0036","article-title":"Reading between the lines: complete blood count-derived parameters as prognostic factors in patients with newly diagnosed acute myeloid leukemia","volume":"19","author":"Stefaniuk","year":"2025","journal-title":"Clinical Med Insights: Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.01.016_bib0037","first-page":"131","article-title":"Prognostic value of neutrophil to lymphocyte ratio in acute myeloid leukemia","volume":"13","author":"Yilmaz","year":"2023","journal-title":"Open J Intern Med"},{"key":"10.1016\/j.clml.2026.01.016_bib0038","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.2147\/CMAR.S245928","article-title":"The neutrophil to lymphocyte and lymphocyte to monocyte ratios as new prognostic factors in hematological malignancies \u2013 a narrative review","volume":"12","author":"Stefaniuk","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2026.01.016_bib0039","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.2147\/OTT.S144438","article-title":"Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia","volume":"10","author":"Song","year":"2017","journal-title":"OncoTargets Ther"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1186\/s12885-022-10231-0","article-title":"Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study","volume":"22","author":"Xiao","year":"2022","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.clml.2026.01.016_bib0041","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32196","article-title":"Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia","volume":"125","author":"Chamoun","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.01.016_bib0042","series-title":"Disclosure: Sarah Lappin Declares no relevant financial relationships with ineligible companies","article-title":"Biochemistry, lactate dehydrogenase","author":"Farhana","year":"2025"},{"key":"10.1016\/j.clml.2026.01.016_bib0043","doi-asserted-by":"crossref","first-page":"103627","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clml.2026.01.016_bib0044","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.21608\/ejhm.2024.352944","article-title":"The effect of elevated serum lactate dehydrogenase level on survival of newly diagnosed acute myeloid leukemia (AML) patients","volume":"95","author":"Shaaban","year":"2024","journal-title":"Egyptian J Hospital Med"},{"issue":"2","key":"10.1016\/j.clml.2026.01.016_bib0045","first-page":"258","article-title":"Predictive factors of fatal bleeding in pediatric acute promyelocytic leukemia (APL)","volume":"14","author":"Manzoor","year":"2025","journal-title":"Pak J Med Dentist"},{"key":"10.1016\/j.clml.2026.01.016_bib0046","article-title":"The clinical characteristics and implications of acute kidney injury during induction therapy for acute promyelocytic leukemia","volume":"16","author":"Shen","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clml.2026.01.016_bib0047","article-title":"Prognostic value of serum lipids in newly diagnosed acute promyelocytic leukemia","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.01.016_bib0048","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1080\/10428190802517732","article-title":"Augmented and standard Berlin\u2013Frankfurt\u2013M\u00fcnster chemotherapy for treatment of adult acute lymphoblastic leukemia","volume":"49","author":"Chang","year":"2008","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.clml.2026.01.016_bib0049","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-136983","article-title":"Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia","volume":"136","author":"Bewersdorf","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2026.01.016_bib0050","first-page":"2777","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz","year":"2014","journal-title":"Blood, J Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0051","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterranean J Hematol Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0052","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-024-01074-y","article-title":"Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia","volume":"14","author":"Wu","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2026.01.016_bib0053","first-page":"775","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood, J Am Soc Hematol"},{"key":"10.1016\/j.clml.2026.01.016_bib0054","article-title":"Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia: a multicenter, non-selected, retrospective cohort study","volume":"14","author":"Kim","year":"2024","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clml.2026.01.016_bib0055","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/leu.2017.71","article-title":"Early death rates remain high in high-risk APL: update from the Swedish acute leukemia registry 1997\u20132013","volume":"31","author":"Lehmann","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.clml.2026.01.016_bib0056","doi-asserted-by":"crossref","unstructured":"Gursoy V., Hunutlu F.C., Pinar I.E., Ozkocaman V., Ozkalemkas F. Comparison of the effectiveness of risk models used in acute promyelocytic leukemia. Int J Hematol Oncol.35(1):113-22.","DOI":"10.4999\/uhod.247566"},{"key":"10.1016\/j.clml.2026.01.016_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-013-0478-y","article-title":"International Society of thrombosis and hemostasis scoring system for disseminated intravascular coagulation\u2265 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia","volume":"30","author":"Mitrovic","year":"2013","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.01.016_bib0058","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MPH.0000000000001280","article-title":"Risk markers for significant bleeding and thrombosis in pediatric acute promyelocytic leukemia; report from the children\u2019s oncology group study AAML0631","volume":"41","author":"Rajpurkar","year":"2019","journal-title":"J Pediatr Hematol\/Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.01.016_bib0059","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood.V126.23.3758.3758","article-title":"Coagulopathy in acute promyelocytic leukemia: strategies to improve assessment of hemostatic risk","volume":"126","author":"David","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:37:02Z","timestamp":1778067422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000303"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Insights Into Acute promyelocytic leukemia (APL) in Egypt in the Absence of Arsenic Trioxide (ATO): Clinical Characteristics, Outcomes and Risk Factors for Early Mortality: A Single Center Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}